Compare · DERM vs OGN
DERM vs OGN
Side-by-side comparison of Journey Medical Corporation (DERM) and Organon & Co. (OGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DERM and OGN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- OGN is the larger of the two at $3.65B, about 29.5x DERM ($123.9M).
- OGN has been more active in the news (11 items in the past 4 weeks vs 4 for DERM).
- OGN has more recent analyst coverage (19 ratings vs 7 for DERM).
- Company
- Journey Medical Corporation
- Organon & Co.
- Price
- -
- -
- Market cap
- $123.9M
- $3.65B
- 1M return
- -
- +1.16%
- 1Y return
- -
- +82.18%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2021
- News (4w)
- 4
- 11
- Recent ratings
- 7
- 19
Journey Medical Corporation
Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Organon & Co.
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
Latest DERM
- SEC Form 10-Q filed by Journey Medical Corporation
- Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Journey Medical Corporation
- Journey Medical Corporation to Participate in September 2026 Investor Conferences
- Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
- SEC Form 10-Q filed by Journey Medical Corporation
- Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Latest OGN
- Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
- Head of Mfg & Supply Drinane Juliana Papa converted options into 3,626 shares and covered exercise/tax liability with 1,242 shares, increasing direct ownership by 13% to 20,859 units (SEC Form 4)
- Head of R&D & CMO Arjona Ferreira Juan Camilo converted options into 6,447 shares and covered exercise/tax liability with 2,314 shares, increasing direct ownership by 11% to 41,565 units (SEC Form 4)
- SVP and Corporate Controller Holzbaur Lynette converted options into 5,456 shares and covered exercise/tax liability with 1,555 shares (SEC Form 4)
- New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
- Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
- Organon Announces Quarterly Dividend
- Organon & Co. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Organon & Co.
- Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors